The Korean Obstructive Lung Disease (KOLD) Cohort Study is a prospective longitudinal study of patients with chronic obstructive pulmonary disease (COPD), asthma, or other unclassified obstructive lung diseases. It was designed to develop new classification models and biomarkers that predict clinically relevant outcomes for patients with obstructive lung diseases. Methods: Patients over 18 years old who have chronic respiratory symptoms and airflow limitations or bronchial hyperresponsiveness were enrolled at 17 centers in South Korea. After a baseline visit, the subjects were followed up every 3 months for various assessments. 
Introduction
Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality worldwide and is associated with substantial socioeconomic burdens which are increasing continuously in many countries 1 . The situation seems particularly serious in Asia because of the high prevalence of tobacco smoking, exposure to outdoor and indoor air pollution related to the burning of wood and other biomass fuels, and exposure to occupational dust 2 . The fourth Korean National Health and Nutrition Examination Survey conducted in Korea revealed that the prevalence of COPD in subjects aged >40 years was 13.4%. However, only a minority of COPD patients still receive physician' s diagnosis or treatment not only in its early stages but even when lung function is severely impaired 3 . One of the main reasons for under-diagnosis and undertreatment of COPD is that the disease progresses slowly and is heterogeneous. Although chronic airflow limitation is one important characteristic of COPD, the disease shows heterogeneous features in terms of clinical presentation, physiology, imaging, response to therapy, decline in lung function, and survival, even in patients that show a similar degree of airflow limitation 4 . This heterogeneity might arise from differences in environmental factors and/or the patient's genetic background. It follows, therefore, that long-term observational cohort studies should be performed in different countries, or regions in which patients of different genetic backgrounds may have been exposed to different disease etiologies to identify the pathogenesis of COPD heterogeneity.
Asia is a very heterogeneous region containing many countries at various stages of development and of varying socioeconomic status. While several cohort studies of COPD are ongoing in Western countries 5, 6 , a few longitudinal studies are being conducted in Asia 7 . Thus, in terms of ethnic heterogeneity, there is a need to activate longitudinal studies of COPD patients across Asia.
The Korean Obstructive Lung Disease (KOLD) Cohort Study is an ongoing prospective longitudinal study that includes patients with COPD, asthma, or other unclassified obstructive lung disease. The aims of the KOLD Cohort Study were to provide a new disease classification of obstructive lung disease, and to identify interactive prognostic factors for obstructive lung disease. The present article describes the design and interim results of the KOLD Cohort Study.
Materials and Methods

Study design
Seventeen centers in South Korea participated in the study. Eleven centers joined in June 2005, and another 6 centers have joined since 2010. Patient screening was based on demographic data, medical history, physical examination, spirometry and a methacholine bronchial provocation test (if forced expiratory volume in 1 second [FEV 1 ] >60% predicted). After an initial enrollment visit, initial outcome measurements were taken and the patients were followed up every 3 months. In addition to regular follow-ups, emergency visits were carried out and outcome measurements were taken when patients experienced exacerbations. The present study was approved by the institutional review board of the Asan Medical Center Institutional Review Board (No. 2005-0345) and by the Institutional Review Boards of the other 16 hospitals taking part. Written informed consent was obtained from all patients.
Subjects
The inclusion criteria for the KOLD Cohort Study were patients over 18 years-of-age with chronic respiratory symptoms as well as one or both of the criteria, airflow limitation or bronchial hyper-responsiveness. "Chronic" was defined as symptoms lasting for more than 3 months, or repeated symptoms experienced at intervals of more than 3 months. Respiratory symptoms were defined as dyspnea, cough, wheeze, or sputum production. Airflow limitation was defined as a prebronchodilator FEV 1 over forced vital capacity (FVC) value of less than 0.7 (FEV 1 /FVC<0.7). Bronchial hyper-responsiveness was measured using the methacholine provocation test, and was defined as the provocative concentration that reduces the FEV 1 by 20% below 16 mg/mL (provocative concentration that reduces the FEV 1 by 20% [PC 20 ]≤16 mg/mL). Unlike other studies, the KOLD Cohort Study did not use smoking history as an inclusion criterion. In addition, patients with bronchial hyper-responsiveness were included. Furthermore, a prebronchodilator FEV 1 /FVC<0.7 was used rather than postbronchodilator FEV 1 /FVC<0.7 to allow the inclusion of asthma and other unclassified obstructive lung disease patients in the study.
Exclusion criteria were patients with co-existing illnesses that would interfere with the study results (e.g., malignancy, congestive heart failure, cerebrovascular disorders, chronic renal failure, diabetes with severe complications, and uncontrolled hypertension), and respiratory diseases other than obstructive lung disease (e.g., previous pulmonary resection, tuberculosis-destroyed lung, and bronchiectasis). Patients with a recent (8 weeks before screening) exacerbation or other respiratory illness (such as upper respiratory infection or pneumonia) were also excluded. However, patients who recovered from an exacerbation and had been stable for more than 8 weeks were included in the study.
Outcome measurement
The evaluation of the KOLD Cohort Study patients is described in Table 1 , along with the measurement intervals. The www.e-trd.org outcome measurements included clinical, pulmonary functional, radiological, genetic outcomes. The clinical outcomes measured were dyspnea (assessed using the modified UK Medical Research Council [MRC] dyspnea scale), exacerbations, patient-reported health outcomes (e.g., Saint George' s Respiratory Questionnaire or COPD Assessment Test), psychological status (depression and anxiety score), sexual function, and comorbidities. Measurements of pulmonary function included spirometry (pre-and post-bronchodilator test), lung volume (body plethysmography) and diffusing capacity for carbon monoxide (single-breath method). Because FEV 1 is the defining characteristic of obstructive lung disease, 
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•: required; ◐: optional; ○: performed 3 months after enrollment, then again 1 year later; ◎: performed 1 year after enrollment, then again 3 years later. . Images of the whole lung were extracted automatically and the attenuation coefficient of each pixel was calculated. Emphysema index (volume fraction of the lung<-950 HU), air trapping index (mean lung density at full expiration over mean lung density at full inspiration), and airway thickening (wall area percentage of two segmental bronchi; RB1 and LB1+2) were used for quantitative assessment using CT. Serum, plasma, DNA and urine samples were collected for biomarker and genetic/proteomic analysis. Other outcome measurements included body composition (measure using whole body impedance), resting oxygen saturation, the 6-minute walk test, airway resistance (measured using impulse oscillometry), and trans-thoracic echocardiography.
Results
From May 2005 to October 2013, a total of 477 subjects were enrolled. All patients were over the age of 40 years (mean age, 66.1±7.9 years). Of these, 433 (91%) were male, 403 (84%) had a smoking history more than 10 pack-years (mean smoking history, 46.3±27.3 pack-years), and 381 (80%) were diagnosed with COPD according to the presence of an airflow limitation that was not fully reversible (post-bronchodilator FEV 1 /FVC<0.7) and a smoking history of more than 10 packyears. To date, 39 (8%) patients have died during follow-up, 110 (23%) ended follow-up in early stages, and 328 (69%) are still being followed-up.
The interim analyses of the KOLD Cohort Study identified various predictors of therapeutic response [8] [9] [10] [11] . These include clinical, pulmonary functional, radiological or combined factors. Genotypes, such as the ADRB2 or CRHR1 gene polymorphisms, were also associated with therapeutic response 12, 13 . The majority of the analyses addressed therapeutic response in lung function to inhaled bronchodilators, either with or without corticosteroids. Combination of clinical and lung function indices was better at predicting acute exacerbations than radiological factors 14 . Radiological assessments made using volumetric CT correlated with clinically meaningful outcomes, such as the BODE index and its components 15 . Volumetric CT was able to quantitatively assess the regional heterogeneity of emphysema, and showed pulmonary function test values were more influenced by the severity of emphysema in the lower lungs than the severity of emphysema in the upper lungs 16 . The ADRB2 gene polymorphism was associated with airway wall phenotypes as measured by CT, suggesting that it may be one of the determining factors of the radiological COPD phenotype 17 . In addition, cluster analysis identified distinct phenotypes in elderly with obstructive lung disease and factors related to pulmonary hypertension in COPD patients 18, 19 . Furthermore, combining the analysis of KOLD with that of the Cohort for Reality and Evolution of Adult Asthma in Korea (COREA) has identified and characterized an overlap syndrome, which is an intermediate between asthma and COPD in clinical characteristics 20 .
Discussion
COPD is a heterogeneous disease that may have different etiologies, pathogenesis, and host responses. A particular COPD phenotype may be related to a distinct natural history and respond differently to treatment. Discovering new COPD phenotypes involves identifying patient groups with unique prognostic or therapeutic characteristics. Originally the term "phenotype" referred to the composite of the observable characteristics or traits of an organism. However, a more concise definition of COPD phenotypes is needed to supersede the currently used descriptions, "blue bloater" and "pink puffer. " Recently, a new definition of the COPD phenotype was suggested as follows: a single or combination of disease attributes that describe difference between individuals with COPD that relate to clinically meaningful outcomes (symptoms, exacerbations, response to therapy, rate of disease progression, or death) 4 . This definition will help to identify the clinically relevant COPD phenotypes.
The 8-year prospective study conducted by Fletcher et al.
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(The Natural History of Chronic Bronchitis and Emphysema, published in 1976) is still the most highly cited summary of COPD natural history. However, it focused primarily on FEV 1 and did not address the natural history of other features of COPD. In addition, the duration of the study was relatively short compared with the natural history of COPD. Because COPD progresses slowly, the heterogeneity of COPD natural history can only be determined by prospective longitudinal studies for longer duration 22 . Recent studies suggest that there are racial differences in terms of COPD susceptibility, treatment, and prognosis [23] [24] [25] . Most of these studies looked at the higher susceptibility of African Americans race to tobacco smoke compared with that of Caucasians. This implies that racial differences also exist in Asians. In addition to racial differences in susceptibility to COPD, a growing number of studies have identified COPD risk factors that are not related to smoking. These risk factors include exposure to indoor and outdoor pollutants, workplace exposure to dust and fumes, a history of repeated lower respiratory-tract infections during childhood, a history of pulmonary tuberculosis or, chronic asthma, intrauterine growth retardation, poor nourishment, and poor socioeconomic status 26 . www.e-trd.org These risks are particularly relevant to non-smoking Asian females. However, it is not clear whether COPD phenotype in non-smokers is different from that in smokers. Therefore, ethnic heterogeneity and risk factors for COPD in non-smoker are points that should be assessed in collaborative COPD research projects conducted across various Asian countries.
The KOLD Cohort Study used different inclusion criteria from those used in other longitudinal studies of COPD. First, the KOLD Cohort Study did not use smoking history as an indispensable inclusion criterion. Although most patients enrolled in the KOLD Cohort Study have smoking history more than 10 pack-years, we leave room to take non-smoker COPD patients. Second, a pre-bronchodilator FEV 1 /FVC<0.7 was used as an inclusion criterion to include patients with COPD as well as asthma and unclassified obstructive lung disease. Third, the KOLD Cohort Study used bronchial hyperresponsiveness as an inclusion criterion. Bronchial hyperresponsiveness is an important predictor of an accelerated decline in FEV 1 and is thought to be second only to cigarette smoking as a significant risk factor for COPD 27, 28 . This flexibility of inclusion criteria used in the KOLD Cohort Study would facilitate to dissect heterogeneity of obstructive lung disease.
As radiologic characterization of COPD with volumetric CT, the low attenuation area and segmental wall area percentage or thickness are used mostly. These indices are associated with various clinical outcomes of COPD 29 . In addition, the KOLD Cohort Study used CT air trapping index as small airway obstruction index. This index, as well as the emphysema index and the segmental wall area percentage, was independently correlated with various clinical parameters of COPD 11, 15 . A better understanding of COPD heterogeneity requires multinational collaborative research. Thus, the Asian Network for Obstructive Lung Disease (ANOLD) has been built as an extension of the KOLD Cohort Study 30 . In the ANOLD, researchers from 12 regions of Asia have participated and recruited more than 1,000 COPD patients since September 2009. The purpose of the ANOLD is to characterize COPD heterogeneity in Asia by determining the relationship between clinical outcomes and various aspects of the disease. A new insight into the pathogenesis and long-term natural history of COPD could be achieved through collaborative research conducted in various Asian countries. Undertaking longitudinal studies for longer duration in Asian COPD patients would enable to discover distinct COPD phenotypes with new therapeutic and prognostic biomarkers.
In conclusion, the KOLD Cohort Study is one of the leading long-term prospective longitudinal studies investigating the heterogeneity of COPD in Asia. Furthermore, in conjunction with the ANOLD, the KOLD Cohort Study is expected to provide new insights into the pathogenesis and long-term progression of COPD.
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